SGLT2 inhibitor Jardiance (empagliflozin) reduced a composite of cardiovascular (CV) death or hospitalisations for heart failure by a significant 21% compared to placebo in HFpEF, regardless of diabetes status, according to results presented at the European Society of Cardiology (ESC) meeting over the weekend.
The improvement compares to a 13% reduction in the same endpoint with Entresto (sacubitril/valsartan) in the PARAGON-HF trial, which secured the first-ever FDA approval in HFpEF earlier this year.
